Vimarsana
Biggest News Aggregation in the World

Page 21 - Roche Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Roche Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Roche Group Today - Breaking & Trending Today

Genentech's Vabysmo Shows Sustained Benefits In Long-Term Studies For Retinal Vein Occlusion - Vimarsana News

Genentech's Vabysmo Shows Sustained Benefits In Long-Term Studies For Retinal Vein Occlusion

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), said that new long-term data for the company's Vabysmo showed sustained retinal drying...

Digital Medicine Society Convenes Industry Leaders to Streamline Path to Commercial Success for Digital Health Product Developers - Vimarsana News

Digital Medicine Society Convenes Industry Leaders to Streamline Path to Commercial Success for Digital Health Product Developers

/PRNewswire/ -- Today, the Digital Medicine Society (DiMe) announced it's partnering with Peterson Health Technology Institute (PHTI), ZS Associates, and other...

VectorY Appoints Khurem Farooq to Board of Directors - Vimarsana News

VectorY Appoints Khurem Farooq to Board of Directors

VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the appointment of industry veteran Khurem Farooq as independent board member, effective...

Why Battered Biotech May Be Turning Around | Chief Investment Officer - Vimarsana News

Why Battered Biotech May Be Turning Around | Chief Investment Officer

This cyclical sector has suffered, post-pandemic, but signs of a recovery are appearing.

Source: ai-cio.com
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types - Vimarsana News

Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received European Commission (EC) marketing authorization of...